OBOlga Bogomolets

Olga Bogomolets

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Olga Bogomolets has a total of 58 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Topical Timolol Beyond Infancy: A Retrospective Study of Its Use in Persistent Infantile Hemangiomas

    by Olga Bogomolets, Sofiia Bogomolets-Sheremetieva

    Infantile hemangiomas (IH) usually undergo spontaneous involution; however, some lesions remain visible after infancy and may cause psychosocial distress in children and their families. Evidence regarding the effectiveness of topical beta-blockers when treatment is initiated after infancy remains limited. This real-world study evaluated the efficacy of topical timolol therapy in children aged 1-5 years with persistent IH. Children with IH were evaluated at a specialized vascular anomalies center in Ukraine between 2019 and 2024. Parents of children older than 1 year with persistent visible IH associated with psychosocial distress were offered vascular laser therapy or topical timolol treatment. Because topical therapy could be administered safely at home under remote medical supervision during ongoing military action, all families chose this option. A short initial treatment period of 2-4 weeks was used to assess the therapeutic response, and treatment was continued if improvement was observed. A total of 2419 children with IH were evaluated during the study period. Among them, 1287 patients used topical timolol as monotherapy. Treatment was initiated after the age of 1 year in 113 patients with persistent lesions. Positive outcomes were observed in 1151 (98.04%) patients who started therapy before the age of 1 year and in 78 (69.03%) patients who initiated treatment between 1 and 5 years of age (p < 0.001). Topical timolol 0.5% demonstrated limited effectiveness in older children, whereas switching to topical timolol 1% resulted in clinical improvement. In six patients previously treated with systemic beta-blockers, topical timolol remained effective even after systemic therapy had lost effectiveness. Natural involution of IHs may be partially responsible for the positive effect observed in some of our patients. These findings suggest that topical timolol 1% may provide clinically meaningful improvement in persistent IH beyond infancy and support telemedicine-based treatment when access to in-person care is limited.

  • Open Access

    Cutaneous-to-Bronchial Rosai–Dorfman Disease without Lymphadenopathy: A Rare Case Report and Literature Review

    by Olga Bogomolets, Roman Hryshchenko, Oleksandr Berezkin, Sofiia Bogomolets-Sheremetieva, Anna Svystak

    Rosai–Dorfman disease (RDD) is a rare non-Langerhans cell histiocytosis that typically presents with massive cervical lymphadenopathy and systemic manifestations. The cutaneous form is usually limited to the skin and rarely progresses to systemic involvement. Timely confirmation of the diagnosis of RDD in cases of progression to systemic involvement is a challenge for the health care system. We report a 23-year-old woman with a history of COVID-19 infection and subsequent mRNA vaccination who developed acneiform eruptions on her face and at the vaccination site on her shoulder. Biopsies confirmed cutaneous RDD without lymphadenopathy. After more than one year of a purely cutaneous course, she developed cough and dyspnea. Imaging revealed an isolated bronchial lesion without lymph node involvement; histology confirmed RDD. The patient responded to local corticosteroid injections and systemic glucocorticoids, with stabilization of the disease. Our report underscores the importance of considering RDD in persistent acneiform eruptions unresponsive to treatment and bronchial masses without lymphadenopathy.


  • Open Access

    Diagnostic value of ultrasound examination of skin melanoma for selecting the optimal treatment tactics

    by R.V. Hryshchenko, O.V. Bogomolets, V.I. Stepanenko, K.O. Chalyy

    Cutaneous melanoma is a malignant tumor characterized by a high risk of both lymphatic and hematogenous metastasis, which represents a negative prognostic factor for affected patients. Although melanoma accounts for only approximately 1% of all skin cancer cases globally, it is responsible for more than 80% of skin cancer-related deaths due to delayed or inaccurate diagnosis. Given the increasing incidence of melanoma, particularly among individuals of Caucasian origin with Fitzpatrick skin phototypes I-II, timely and accurate diagnosis is of critical importance. High-frequency ultrasound (HFUS) is a non-invasive and safe imaging modality that enables the assessment of tumor invasion depth and skin structure prior to surgical intervention. The aim of this study was to evaluate the diagnostic performance of high-frequency ultrasound using a 20-22 MHz probe for the preoperative visualization and assessment of cutaneous melanoma, through comparison with histopathological examination (HPE) data. Specifically, the study analyzed the effectiveness of a linear ultrasound probe with a frequency range of 10-22 MHz on the General Electric LOGIQ E R8 (USA) system, in comparison to the 22 MHz DUB Skinscanner (Germany), for determining tumor invasion depth. Additionally, the study established the statistical correlation between HFUS and histopathological findings, to justify the integration of HFUS into clinical diagnostic algorithms for melanoma as a non-invasive tool for preoperative assessment. A total of 90 patients with dermoscopically suspected melanoma were examined. The results of preoperative HFUS performed with two systems – GE LOGIQ E R8 (USA), using a linear transducer with a central frequency of 10-22 MHz, and the DUB Skinscanner (Germany), with a 22 MHz linear transducer were compared to histopathological data. Based on the results of the statistical analysis, the GE ultrasound system demonstrated a very high level of concordance with histopathological measurements, significantly outperforming the DUB device. These findings support the incorporation of high-frequency ultrasound into the diagnostic algorithm for patients with cutaneous melanoma as a non-invasive and informative method for preoperative evaluation.

  • Cutaneous Rosai–Dorfman disease: a comprehensive literature review and two case reports

    by Olga Bogomolets, Roman Hryshchenko, Olexandr Berezkin

    Introduction: Cutaneous Rosai-Dorfman disease is a rare form of histiocytosis. There are no established standards for its treatment, and some patients have minimal or no response. To date, no published reports have described disease progression in cutaneous Rosai-Dorfman disease in relation to specific treatment modalities. Material and methods: The patients were examined at the Department of Dermatology of the Dr. Bogomolets Institute of Dermatology and Cosmetology in Kyiv, Ukraine. Ultrasound imaging was performed using a linear transducer. Dermoscopy was performed using a digital video dermatoscope. Formalin-fixed paraffin-embedded tissue samples were processed using standard protocols. Qualitative assessment of tissue morphology was performed using commercially available Series S histological stains (Epredia, Kalamazoo, MI, USA). Immunohistochemical staining was carried out using a ready-to-use anti-S100 antibody. A literature search was conducted via PubMed using the keyword combination 'cutaneous Rosai-Dorfman disease'. Results: Two cases of cutaneous Rosai-Dorfman disease in Caucasian female patients are reported. One patient exhibited disease exacerbation following rapid tapering of systemic corticosteroids and another one after exposure to doxycycline. Diagnosis was confirmed by histopathologic evaluation and S100-positive immunohistochemical staining. Conclusions: Further clinical studies on the treatment of cutaneous Rosai-Dorfman disease, including data on therapeutic outcomes (complete and partial responses) and treatment-related exacerbations, are needed to optimize clinical management and improve patient outcomes.


  • Open Access

    Urgent Treatment of Complicated Ulcerated Infantile Hemangioma with β-Blockers via Telemedicine: A Case Report

    by Olga Bogomolets, Magdalena Wierzbik-Strońska, Roman Hryshchenko, Catherine Bogomolets

    Introduction: Infantile hemangiomas (IH) exacerbated by ulceration invariably necessitate hospitalization, although simple IHs are sometimes managed remotely. Furthermore, according to international regulations, β-blocker medication for such hemangiomas should be systemic and performed in a clinic, especially if there is infection and risk of bleeding. Case: War in Ukraine made it impossible to hospitalize and properly examine a patient with a complex ulcerated and infected IH, forcing us to administer β-blocker timolol therapy only through telemedicine. Conclusions: Our case demonstrates the possibility of successful distant treatment of IH with ulcer using only a topical β-blocker carried out remotely through telemedicine, which is critical in the context of the COVID-19 pandemic, war, hostilities, or natural disasters where inpatient treatment is not available.


  • Open Access

    Treatment of infantile hemangioma with topical β-blockers in pediatric practice: a review of the literature

    by Kyiv Ukrainian Military Medical Academy, O.V. Bogomolets, Katowice Academy Of Silesia, O.V. Selyuk, K.P. Bogomolets, S.O. Bogomolets-Sheremetieva

    The purpose of this review is to acquaint the audience with the benefits of infantile hemangioma (IH) treatment with local β-blockers, which are safe for the child, allow for the complete cure of hemangiomas without surgery, complications, scars, and cosmetic defects, and have practically no systemic side effects. We aimed to analyze the effectiveness and limitations of the use of local β-blockers, to show the possibility and expediency of IH management in pediatric practice, and to demonstrate that the goal of therapy is not the treatment of complications, but the prevention of their occurrence and complete resolution of the hemangioma without surgical intervention. The use of topical β-blockers, such as timolol gel or solution, provides a non-surgical, non-invasive treatment option for IH, minimizing the systemic exposure and possible side effects associated with oral β-blockers. Local treatment is best started before the age of 2 months - at an early stage, when IHs are small in size, potentially preventing the need for more invasive treatment methods. Topical use is associated with a lower risk of systemic side effects, such as hypotension or bradycardia, that can occur with oral β-blockers. Topical treatment can be applied at home, which can be more convenient for parents and caregivers, and also increases the opportunity for treatment and follow-up by pediatricians. In case of natural disasters or military operations, treatment can be done remotely using teledermatology. The effectiveness of local β-blockers mostly depends on the age at which treatment was started: the earlier it was started, the higher the effectiveness. Treatment of complicated IH with deep soft tissue, mucosal, or airway involvement usually requires a combination of systemic propranolol and topical β-blockers or other interventions such as laser therapy. The choice of treatment should be selected individually according to the degree of risk of IH, its size, localization, child's age, weight, and other parameters in each clinical case. β-adrenoblockers are the most modern, effective, non-surgical, and safe method of treating IH, they can be used both for systemic and local application. IH can be successfully treated by pediatricians and dermatologists. No conflict of interests was declared by the authors.

  • Open Access

    Analysis of the modern treatment protocols for complicated and uncomplicated infantile hemangiomas. Literature review and own data

    by Kyiv Ukrainian Military Medical Academy, O.V. Bogomolets, Katowice Academy Of Silesia, R.V. Hryshchenko, M.V. Pavelko, I.O. Krishchenko, S.O. Bogomolets-Sheremetieva

    Infantile hemangioma (IH), a benign tumor of the vascular endothelium, is the most common type of vascular pathology of the infant’s skin, which grows and significantly increases in size mostly during the first 12 months of a child's life. Statistics indicate that IH affects up to 10% of newborns and children aged <1 year. The proliferative activity of IHs during the first year of a child's life differs significantly and could mislead parents and doctors. Lack of timely treatment at an early stage leads to an increase in the size of the tumor and high risks of cosmetic defects. Thus, the proliferation of IH can cause a gross deformation of the skin and a dysfunction of nearby organs. Purpose - to analyze modern data on the treatment of patients with complicated and uncomplicated hemangiomas, to study international experience and compare it with own observations and own experience, and to improve patient treatment protocols. In this review, we analyzed 19 articles involving more than 2400 children with different types of IH, compared different treatment protocols, their outcomes, and complications, and demonstrated our methods, results, and clinical cases. It may be resumed that β-blockers are “first-line” drugs for local and systemic treatment of IHs, as they allow slowing of the proliferation and activating resorption of the tumor without cosmetic defects or complications. Treatment of IH in babies following modern treatment protocols should be carried out non-surgically, without operations, anesthesia, scars, or cosmetic defects. Ulceration is the most common complication of IHs and the result of the late start of the treatment and thus could be prevented by the timely beginning of the therapy. No conflict of interests was declared by the authors.

  • Open Access

    Pigmented Poroma of the Lower Eyelid: A Case Report and Literature Review

    by Olga Bogomolets, Ewa Rojczyk, Roman Hryshchenko, Catherine Bogomolets, Oleksandr Berezkin

    BACKGROUND Eyelid tumors belong to a diverse group of neoplasms ranging from benign lesions to malignant tumors. Poromas are common, benign, mostly unpigmented tumors of the epidermal sweat duct unit, that usually grow slowly and occur in elderly people on the palms and soles. In most poroma cases some gene fusions were detected, which were caused by chromosomal aberrations. CASE REPORT We report the atypical case of a 30-year-old female patient suffering for more than 15 years from a solitary, polypoid, pigmented formation with a focal tuberous surface on the left lower eyelid. The lesion was not growing during the first years, but in the last 6 months before diagnosis its size more than doubled, finally reaching 12×14 mm. It was removed and histopathological analysis confirmed the diagnosis of a rare tumor - a poroma. There were no complications during healing and no recurrence was reported. CONCLUSIONS There have so far been only 9 reports of eyelid poromas, and the presented case significantly differed from the previous ones, as it appeared at an early age and showed rapid growth during a short time due to the war-related acute psychological stress. Moreover, it had unusual pigmentation and unpleasant smell. Reporting such untypical cases is clinically important because it is crucial to be aware of the diversity of eccrine poroma manifestation to distinguish it from malignant lesions.


  • Open Access

    Benign and malignant (melanocytic and non-melanocytic) skin neoplasms: classification, clinical manifestations, diagnosis and treatment tactics (analysis of modern specialized literature and own clinical observations and diagnostic researches)

    by R.V. Hryshchenko, O.V. Bogomolets, V.I. Stepanenko

    Objective — to analyze the currently existing classifications, possible causes, localization, clinical pattern and course of a number of benign and malignant skin neoplasms, as well as to determine the informative value of modern diagnostic methods (dermatoscopy, high-frequency ultrasound) in order to choose rational treatment tactics. Materials and methods. Based on the analysis of the literature and the results of own clinical observations, dermatoscopic and high-frequency ultrasound diagnostic examinations, the clinical manifestations and morphological signs of a number of benign and malignant skin neoplasms are systematized. Results and discussion. At the current stage, imaging methods of diagnosis occupy a leading place in the diagnosis of benign and malignant neoplasms of the skin. Relevant diagnostic methods include dermatoscopy and digital dermatoscopy with using artificial intelligence, high-frequency ultrasound, confocal microscopy and optical coherence tomography. Particular attention is paid to the diagnostic significance of high-frequency ultrasound, which allows non-invasive, real-time determination of the size and depth of invasion and assessment of the boundaries of benign and malignant skin tumors. The results of our own clinical observations and dermoscopic and high-frequency ultrasound examinations of a number of benign and malignant skin tumors are also presented, with a discussion of the received data. Conclusions. Considering a rather large number of nosologies of benign and malignant skin tumors and their clinical variations, it is important to establish the correct diagnosis in a timely manner. Currently, imaging methods for diagnosing benign and malignant skin tumors, in particular, dermoscopy, high-frequency ultrasound, confocal microscopy and optical coherence tomography, are being actively introduced in dermatological practice. High-frequency ultrasound diagnostics of skin neoplasms is a sufficiently informative method that allows non-invasive, real-time determination of the size and depth of invasion, as well as the stage of proliferation of benign and malignant skin neoplasms. The combined use of dermatoscopy and high-frequency ultrasound diagnostics is important for the preliminary differentiation of benign and malignant skin neoplasms. This allows choosing a rational individual treatment tactic, as well as monitoring the effectiveness of the therapy.

  • Open Access

    Covid-19, leukemia, and secondary malignancies of the skin – is there a connection: a case report and literature analysis

    by Olga Bogomolets, Ewa Rojczyk, Roman Hryshchenko, Catherine Bogomolets, Oleksandr Berezkin

    We report the case of a patient who was diagnosed with two melanomas and one skin cancer within two years. Of particular interest was the fact, that at the time these tumors were diagnosed, the patient was already suffering from chronic myeloid leukemia, which developed three months after recovering from Covid-19. From the time of leukemia occurrence, the patient has been taking the tyrosine kinase inhibitor (TKI) - Gleevec. Thus, we took into the account the possibile effect of Gleevec administration on the risk of skin tumor appearance. It was also important to analyze the impact of the SARS-CoV-2 virus and chronic myeloid leukemia on the risk of secondary malignancies. According to so far published data, the direct relationship between Gleevec treatment and the occurrence of skin cancers cannot be proved. However, literature data indicate a direct and indirect relationship between SARS-CoV-2 infection and an increased incidence of carcinogenesis.